Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros








Intervalo de año
1.
Acta Pharmaceutica Sinica ; (12): 1146-1151, 2006.
Artículo en Chino | WPRIM | ID: wpr-294873

RESUMEN

<p><b>AIM</b>To investigate the chemosensitivity to lidamycin (C-1027) in mdr1 gene overexpressing cancer cell lines established by drug induction and by gene-transfection.</p><p><b>METHODS</b>DNA was cloned by RT-PCR and then eukaryotic expressing recombinant plasmid pcDNA3. 1/mdrl was constructed. Using Lipofectamine 2000, a strain of stably transfected human hepatoma cancer cells, HepG2/mdrl, was obtained. The mdr1 mRNA level, P-glycoprotein (P-gp) level and the activity of P-gp to extrude drugs in cancer cells were determined by RT-PCR, immunofluorescence analysis and rhodamine 123 efflux assay. The chemosensitivity of cancer cells with low or high mdr1 expression to lidamycin and other antitumor drugs was tested by MTT assay.</p><p><b>RESULTS</b>The mdr1 mRNA and P-gp levels in KBv200, MCF-7/ADR, and stably transfected HepG2/mdr1 cells were much higher than that in respective parent KB, MCF-7 and HepG2 cells. The IC50 values of lidamycin for KBv200, MCF-7/ADR and HepG2/mdrl cells were (0.24 +/- 0.20) nmol x L(-1), (0.028 +/- 0.011) nmol x L(-1), and (0.020 +/- 0.011) nmol x L(-1), respectively. Compared with parental cells, the values of resistant fold for KBv200, MCF-7/ADR and HepG2/mdr1 cells to lidamycin were 6.8, 1.6 and 1.3 fold; to adriamycin were 37.2, 181.3 and 8.8 fold; to taxol were 336.8, 49.2 and 40.3 fold, respectively.</p><p><b>CONCLUSION</b>Lidamycin is highly active to multidrug resistant cancer cells. The chemosensitivity of those resistant cancer cells to lidamycin is approximately at the similar level as that of parent cancer cells.</p>


Asunto(s)
Humanos , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP , Genética , Aminoglicósidos , Farmacología , Antibióticos Antineoplásicos , Farmacología , Línea Celular Tumoral , Resistencia a Múltiples Medicamentos , Resistencia a Antineoplásicos , Enediinos , Farmacología , Genes MDR , Neoplasias , Quimioterapia , Patología , Transfección
2.
Acta Pharmaceutica Sinica ; (12): 254-258, 2004.
Artículo en Inglés | WPRIM | ID: wpr-301102

RESUMEN

<p><b>AIM</b>To determine the anti-angiogenic activity of emodin.</p><p><b>METHODS</b>Chick embryo assay and cultured endothelial cells were used.</p><p><b>RESULTS</b>Emodin at doses of 150 and 300 microg/egg caused 37.6% and 63.2% inhibition of angiogenesis, respectively. Emodin was shown to inhibit the proliferation of primary cultured bovine aortic endothelial cells in the absence or presence of basic-fibroblast growth factor (bFGF) or the presence of vascular endothelial growth factor (VEGF) in a dose-dependent manner. The IC50 values by MTT assay were 5.56, 8.40 or 6.91 mg x L(-1), respectively. Emodin at concentrations from 5.4 to 21.6 mg x L(-1) induced apoptosis of endothelial cells for 37.6% to 72.6%. Emodin caused endothelial cell cycle arrest at G2/M phase. After emodin treatment, there was a down-regulation of Cyclin B1, P34cdc2, and Bcl-2 protein expression while the Bax protein expression was unaffected.</p><p><b>CONCLUSION</b>Emodin shows anti-angiogenic activity and might be useful for the development of novel anti-cancer therapy.</p>


Asunto(s)
Animales , Bovinos , Embrión de Pollo , Aorta , Biología Celular , Apoptosis , Proteína Quinasa CDC2 , Metabolismo , Ciclo Celular , División Celular , Células Cultivadas , Ciclina B , Metabolismo , Ciclina B1 , Emodina , Farmacología , Células Endoteliales , Biología Celular , Metabolismo , Factor 2 de Crecimiento de Fibroblastos , Farmacología , Neovascularización Fisiológica , Proteínas Proto-Oncogénicas c-bcl-2 , Metabolismo , Factor A de Crecimiento Endotelial Vascular , Farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA